Tilson Financial Group Inc. Acquires 132 Shares of Merck & Co., Inc. (NYSE:MRK)

Tilson Financial Group Inc. lifted its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 2.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,965 shares of the company’s stock after acquiring an additional 132 shares during the period. Tilson Financial Group Inc.’s holdings in Merck & Co., Inc. were worth $446,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Barnes Dennig Private Wealth Management LLC bought a new position in Merck & Co., Inc. during the first quarter valued at approximately $27,000. Promus Capital LLC bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $30,000. WealthTrak Capital Management LLC bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $35,000. MorganRosel Wealth Management LLC bought a new position in Merck & Co., Inc. during the first quarter valued at approximately $36,000. Finally, Spurstone Advisory Services LLC bought a new position in Merck & Co., Inc. during the fourth quarter valued at approximately $37,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 1.7%

Shares of NYSE MRK opened at $80.97 on Friday. The company has a quick ratio of 1.16, a current ratio of 1.41 and a debt-to-equity ratio of 0.69. The business has a fifty day simple moving average of $79.24 and a two-hundred day simple moving average of $87.18. The firm has a market cap of $203.32 billion, a PE ratio of 11.79, a price-to-earnings-growth ratio of 0.85 and a beta of 0.39. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $129.93.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported $2.22 EPS for the quarter, topping the consensus estimate of $2.16 by $0.06. The firm had revenue of $15.53 billion during the quarter, compared to analyst estimates of $15.59 billion. Merck & Co., Inc. had a return on equity of 43.23% and a net margin of 27.27%. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.07 EPS. Analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 8th. Investors of record on Monday, June 16th will be paid a dividend of $0.81 per share. This represents a $3.24 dividend on an annualized basis and a dividend yield of 4.00%. The ex-dividend date of this dividend is Monday, June 16th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 47.16%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on MRK. Guggenheim reissued a “buy” rating and set a $115.00 price target on shares of Merck & Co., Inc. in a research note on Thursday, April 17th. Cantor Fitzgerald lowered Merck & Co., Inc. from an “overweight” rating to a “cautious” rating in a research note on Tuesday, May 20th. Wall Street Zen downgraded Merck & Co., Inc. from a “strong-buy” rating to a “buy” rating in a research report on Friday, April 25th. Finally, Citigroup restated a “neutral” rating and set a $84.00 price objective (down from $115.00) on shares of Merck & Co., Inc. in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $109.19.

View Our Latest Report on Merck & Co., Inc.

Insider Buying and Selling at Merck & Co., Inc.

In related news, SVP Dalton E. Smart III sold 4,262 shares of the company’s stock in a transaction on Friday, April 25th. The stock was sold at an average price of $82.76, for a total transaction of $352,723.12. Following the completion of the sale, the senior vice president directly owned 7,778 shares in the company, valued at $643,707.28. This represents a 35.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.13% of the stock is owned by company insiders.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.